Literature DB >> 27510563

Ectopic expression of MCAM/MUC18 increases in vitro motility and invasiveness, but decreases in vivo tumorigenesis and metastasis of a mouse melanoma K1735-9 subline in a syngeneic mouse model.

Guang-Jer Wu1,2.   

Abstract

Ectopic expression of MCAM/MUC18, a cell adhesion molecule in the immunoglobulin-like gene superfamily, induces two moMCAM/MUC18-minus, non-metastatic mouse melanoma K1735 sublines, K3 (tumor+/metlow) and K10 (tumor-/metlow), to metastasize to lungs in a syngeneic C3H mouse model. In this report, we extended investigation of effects of moMCAM/MUC18 expression on tumorigenesis and metastasis in another lowly metastatic, however highly tumorigenic moMCAM/MUC18-minus mouse melanoma K1735 subline, K9 (tumor+++/metlow). We transfected this subline with the moMCAM/MUC18 cDNA, selected for G418-resistant clones with different expression levels of moMCAM/MUC18, and used them for testing effects of MCAM/MUC18 expression on in vitro growth rate, motility, and invasiveness, in vivo subcutaneous tumor growth, and pulmonary metastasis in syngeneic C3H brown mice. Similar to K3 and K10 cells, increased expression of MCAM/MUC18 in K9 cells did not significantly affect in vitro growth rate, but increased in vitro motility and invasiveness. Surprisingly, increased expression of MCAM/MUC18 in K9 cells decreased their induction of tumorigenesis and suppressed their establishment of pulmonary nodules in syngeneic C3H brown mice. We concluded that increased MCAM/MUC18 expression in K9 subline increased in vitro epithelial-to-mesenchymal transition; however, it suppressed in vivo tumorigenicity and metastasis. Thus MCAM/MUC18 acts as a tumor and metastasis suppressor for the K9 subline, different from its role in other K1735 sublines, K3 and K10. Different intrinsic co-factors in different K1735 sublines, which modulate the functions of MCAM/MUC18 in the cells that interact differently to the tumor microenvironment, may render sublines manifest differently in tumorigenicity and metastasis in vivo.

Entities:  

Keywords:  C3H syngeneic mouse model; Experimental metastasis; MCAM/MUC18; Motility and invasiveness; Mouse melanoma K1735 subline #9; Orthotopic tumorigenesis

Mesh:

Substances:

Year:  2016        PMID: 27510563     DOI: 10.1007/s10585-016-9812-z

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  29 in total

Review 1.  Cell adhesion and signalling by cadherins and Ig-CAMs in cancer.

Authors:  Ugo Cavallaro; Gerhard Christofori
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

2.  CD146 (Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of lymphocyte subset activation in normal peripheral blood.

Authors:  Mohamed F Elshal; Sameena S Khan; Yoshiyuki Takahashi; Michael A Solomon; J Philip McCoy
Journal:  Blood       Date:  2005-10-15       Impact factor: 22.113

3.  MUC18/MCAM (CD146), an activation antigen of human T lymphocytes.

Authors:  W F Pickl; O Majdic; G F Fischer; P Petzelbauer; I Faé; M Waclavicek; J Stöckl; C Scheinecker; T Vidicki; H Aschauer; J P Johnson; W Knapp
Journal:  J Immunol       Date:  1997-03-01       Impact factor: 5.422

4.  CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer.

Authors:  Qiqun Zeng; Weidong Li; Di Lu; Zhenzhen Wu; Hongxia Duan; Yongting Luo; Jing Feng; Dongling Yang; Li Fu; Xiyun Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-30       Impact factor: 11.205

5.  Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix.

Authors:  A Passaniti; J T Isaacs; J A Haney; S W Adler; T J Cujdik; P V Long; H K Kleinman
Journal:  Int J Cancer       Date:  1992-05-08       Impact factor: 7.396

6.  Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression.

Authors:  Maya Zigler; Gabriel J Villares; Andrey S Dobroff; Hua Wang; Li Huang; Russell R Braeuer; Takafumi Kamiya; Vladislava O Melnikova; Renduo Song; Ran Friedman; Rhoda M Alani; Menashe Bar-Eli
Journal:  Cancer Res       Date:  2011-04-05       Impact factor: 12.701

7.  Enforced expression of METCAM/MUC18 increases tumorigenesis of human prostate cancer LNCaP cells in nude mice.

Authors:  Guang-Jer Wu; Mei-Whey H Wu; Changsheng Wang; Yuan Liu
Journal:  J Urol       Date:  2011-02-19       Impact factor: 7.450

8.  Differential expression of CD146 in tissues and endothelial cells derived from infantile haemangioma and normal human skin.

Authors:  Qing Li; Ying Yu; Joyce Bischoff; John B Mulliken; Bjorn R Olsen
Journal:  J Pathol       Date:  2003-10       Impact factor: 7.996

9.  A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo.

Authors:  Eric C McGary; Amy Heimberger; Lisa Mills; Kristy Weber; Gary W Thomas; Mikhail Shtivelband; Dina Chelouche Lev; Menashe Bar-Eli
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

10.  Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells.

Authors:  Guang-Jer Wu; Qiong Peng; Pingping Fu; Shur-Wern Wang; Cheng-Feng Chiang; Dirck L Dillehay; Mei-Whey H Wu
Journal:  Gene       Date:  2004-03-03       Impact factor: 3.688

View more
  3 in total

1.  MRTFB suppresses colorectal cancer development through regulating SPDL1 and MCAM.

Authors:  Takahiro Kodama; Teresa A Marian; Hubert Lee; Michiko Kodama; Jian Li; Michael S Parmacek; Nancy A Jenkins; Neal G Copeland; Zhubo Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-05       Impact factor: 11.205

2.  Dual Roles of METCAM in the Progression of Different Cancers.

Authors:  Guang-Jer Wu
Journal:  J Oncol       Date:  2012-03-28       Impact factor: 4.375

Review 3.  METCAM/MUC18 Decreases the Malignant Propensity of Human Ovarian Carcinoma Cells.

Authors:  Guang-Jer Wu
Journal:  Int J Mol Sci       Date:  2018-09-29       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.